Lavipharm

Lavipharm S.A. is a Greek pharmaceutical company founded in 1911 by the Lavidas family. The business is described as an integrated pharmaceutical group because its activities extend across the development, manufacture, marketing, and distribution of healthcare products rather than being limited to a single stage of the pharmaceutical supply chain. Its portfolio and commercial scope encompass pharmaceutical products, cosmetics, veterinary products, and consumer-health offerings. The company’s historical base is Greece, where it operates as a domestic pharmaceutical enterprise serving healthcare and consumer markets. It has also maintained international activity in France, Cyprus, and the United States, giving the brand a cross-border presence while remaining closely associated with the Greek pharmaceutical sector. The available reference material does not identify specific product names, therapeutic areas, acquisition history, or detailed corporate subsidiaries, so those aspects cannot be described reliably here. A notable corporate milestone was Lavipharm’s listing on the Athens Stock Exchange in 1995. The listing marked a transition from a long-established family-founded enterprise into a publicly traded company and provided a formal capital-markets dimension to its operations. No ticker symbol or detailed listing information is supplied in the available sources. Lavipharm’s positioning is therefore best understood as that of a diversified healthcare company combining pharmaceutical manufacturing and commercial distribution with adjacent categories such as cosmetics, veterinary care, and consumer health. Its integrated model allows the brand to address several healthcare-related markets, while its international operations extend beyond Greece into selected European and North American markets. The supplied reference does not provide enough current corporate information to confirm leadership, ownership structure beyond the company’s family origins, current financial performance, or the precise status of individual brands and products.

Lavipharm was established in 1911 by the Lavidas family in Greece. The available historical reference characterizes it as the largest integrated Greek pharmaceutical company, reflecting a business model that combines several functions normally distributed across separate parts of the healthcare value chain. These functions include pharmaceutical development, manufacturing, marketing, and distribution. Over its history, Lavipharm expanded its scope beyond medicines into cosmetics, veterinary products, and consumer-health goods. This diversification placed the company within a broader healthcare and personal-care environment rather than limiting it to prescription pharmaceuticals. The source material does not provide a detailed account of particular product launches, manufacturing facilities, research programs, or changes in management, so no further historical claims can be made with confidence. The company’s international activity includes France, Cyprus, and the United States. These markets indicate that Lavipharm’s commercial reach has extended outside Greece, although the available material does not specify the dates, scale, local subsidiaries, or distribution arrangements associated with each market. In 1995, Lavipharm was listed on the Athens Stock Exchange. This was a significant corporate-development milestone because it placed the long-established family-founded company within Greece’s public equity market. The available reference does not identify the company’s ticker, offering details, market capitalization, or subsequent capital-market events. Lavipharm remains associated with the Greek pharmaceutical industry and is described as operating internationally. Beyond its founding, diversified healthcare scope, international presence, and 1995 listing, the supplied sources contain limited verifiable detail about the company’s later evolution. Product-level history, executive succession, financial results, corporate transactions, advertising campaigns, regulatory matters, and controversies are therefore left unreported rather than inferred.

• 1995

  Athens Stock Exchange listing

  [1]Lavipharmen.wikipedia.org

  Lavipharm was listed on the Athens Stock Exchange, marking a major corporate-finance milestone for the family-founded pharmaceutical business.

• 1911

  Company founded

  [1]Lavipharmen.wikipedia.org

  Lavipharm was founded in Greece by the Lavidas family and began the corporate history that led to its development as an integrated pharmaceutical company.

An integrated Greek healthcare company spanning pharmaceuticals, cosmetics, veterinary products, and consumer health, with manufacturing, marketing, and distribution capabilities.

• Pharmaceuticals

  Pharmaceutical products

  Pharmaceutical products form the core of Lavipharm’s healthcare portfolio. The company is described as participating in development, manufacturing, marketing, and distribution, but the available reference does not identify individual medicines, active ingredients, therapeutic classes, or product brands.

• Personal care

  Cosmetics

  Lavipharm also operates in cosmetics, extending its activities into personal-care products adjacent to its pharmaceutical business. Specific cosmetic brands, formulations, and launch dates are not identified in the supplied sources.

• Veterinary healthcare

  Veterinary products

  Veterinary products are included among Lavipharm’s business areas. The available material does not specify whether these offerings are manufactured internally, licensed, or distributed, nor does it name individual veterinary products.

• Consumer health

  Consumer-health products

  Consumer-health products broaden Lavipharm’s offer beyond medicines supplied through conventional pharmaceutical channels. No specific product families, brands, or consumer campaigns are documented in the provided reference.

1. 1Lavipharmen.wikipedia.org